NICE - Endorsed Technology Appraisals 2011/2012

It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.

Technology Appraisal Endorsement Process

The following technology appraisals were endorsed during 2011-12 using the process that came into effect on 28 September 2011.  Information on technology appraisals endorsed in previous years can be found on the homepage

Fully Endorsed

March 2012

February 2012

January 2012

December 2011

November 2011

Endorsed With Caveats

November 2011

  • TA75 - Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (related to TA200
    • This guidance has been partially updated by ‘Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C’ NICE Technology Appraisal guidance TA200. The elements of TA75 which have been updated and replaced are:
    • section 1.2, bullet 3 only
    • section 1.4 of TA75 for adults who are eligible for shortened courses of combination therapy (as described in section 1.2 of TA200)
    • section 1.7, bullet 1 only
    • All other recommendations in TA75 still stand
       
  • TA187 - Infliximab (review) and adalimumab for the treatment of Crohn's disease (Includes a review of NICE Technology Appraisal TA40) 
    • It should be noted that continued therapy should be carefully reconsidered in a patient not responding to infliximab and adalimumab in the treatment of Crohn’s disease in accordance with the time period set out in the respective manufacturers’ Summary of Product Characteristics.

  • TA200 - Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (related to TA75
    • In June 2011, sections 3.11, 3.12 and 4.1.5 of the guidance were amended to correct an error in the stated dose of ribavirin.  The doses of ribavirin should be in mg (milligrams), and not micrograms.  Any copies of the guidance printed before this date should be destroyed

Not Endorsed as Applicable to Northern Ireland 

None 

Endorsed Under Previous Process 


The following NICE Technology Appraisals were endorsed by DoH during 2011-12 under the process which was in place prior to 28 September 2011. 

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA86 - Imatinib for the treatment of unresectable and / or metastatic Gastrointestinal Stromal Tumours (Note: This guidance has been partially updated by TA209)

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA191 - Capecitabine for the treatment of Advanced Gastric Cancer

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA192 - Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA201 -  Omalizumab for the Treatment of Severe Persistent Allergic Asthma in Children aged 6-12 Years

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA202 - Ofatumumab for the Treatment of Chronic Lymphocytic Leukaemia Refractory to Fludarabine and Alemtuzumab

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA204 -  Denosumab for the Prevention of Osteoporotic Fractures in Postmenopausal Women

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA205 -  Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA209 - Imatinib for the treatment of unresectable and / or metastatic Gastrointestinal Stromal Tumours (Part update of NICE TA86)

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA212 - Colorectal Cancer (metastatic) - Bevacizumab in combination with Oxaliplatin & either 5-fluorouracil plus Folinic Acid or Capecitabine

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA213 - Aripiprazole for Schizophrenia in People Aged 15-17 Years

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA214 - Bevacizumab in Combination with a Taxane for the First-line Treatment of Metastatic Breast Cancer

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA217 - Donepezil, Galantamine, Rivastigmine and Memantine for the treatment of Alzheimer's disease

Back to top